It has been suggested that the lower thrombosis rates observed in fostamatinib-treated ITP patients may in part be due to its inhibition of platelet CLEC-2, which signals via the same pathway as GPVI [26,27]. Here, CLEC1B is linked to autoimmune thrombocytopenic purpura.